Aton Ra Partners Blueprint Medicines Corp Transaction History

Aton Ra Partners

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$45.23 - $70.15 $610,831 - $947,375	-13,505 Closed	0 $0
Q1 2022 May 16, 2022	BUY	$54.1 - $110.08 $21,315 - $43,371	394 Added 3.01%	13,505 $863,000
Q4 2021 Feb 14, 2022	BUY	$94.25 - $115.99 $82,280 - $101,259	873 Added 7.13%	13,111 $1.4 Million
Q3 2021 Nov 15, 2021	BUY	$80.98 - $109.47 $68,104 - $92,064	841 Added 7.38%	12,238 $1.26 Million
Q2 2021 Aug 12, 2021	BUY	$82.78 - $101.0 $221,353 - $270,074	2,674 Added 30.65%	11,397 $1 Million
Q1 2021 May 17, 2021	BUY	$90.71 - $108.28 $180,603 - $215,585	1,991 Added 29.58%	8,723 $848,000
Q4 2020 Feb 19, 2021	BUY	$92.08 - $124.48 $619,882 - $837,999	6,732 New	6,732 $755,000

351

60.3M

2.25M

1.18M

Ticker BPMC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,719,600
Market Cap $5.4B
Description
Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibit...

Get notified when there are updates to the investment portfolio of Aton Ra Partners, based on Form 13F filings with the SEC.

Stay updated on Aton Ra Partners with notifications on news.